2015-09-09 11:28:20 UTC

FDA Approves New Submucosal Injection

Sept. 8, 2015

The injectable composition is designed for use during upper and lower endoscopic procedures.

FDA has approved Cosmo Pharmaceuticals’ request for marketing authorization of SIC 8000, an injectable liquid composition for use as a submucosal injection agent.

The injectable composition is used during endoscopic mucosal resection (EMR), endoscopic mucosal dissection (ESD) and polypectomy procedures in the gastrointestinal tract. The device is intended for use in endoscopic procedures in the upper and lower intestinal tract, such as the esophagus, stomach, small intestine, colon, sigmoid colon and rectum, as a submucosal injectable agent during the removal of polyps, adenomas, early stage cancers and other pathological lesions by EMR, ESD or polypectomy.

SIC is injected through a standard commercially available endoscopic injection needle, which is inserted into the working channel of the endoscope. The agent, when injected, creates a cushion in situ by lifting the gastrointestinal mucosa from the submucosal layer, allowing the endoscopist to perform an easy and safe resection procedure. 

More on Colonoscopy

Important Opportunity to Advise CMS on Colonoscopy Episode

Oct. 26, 2017

It is critical that you share your feedback with CMS by Wednesday, Nov. 15.

Tips to Avoid a 2019 Payment Penalty

Oct. 19, 2017

Report on one measure for one patient for the 2017 Quality Payment Program Performance Year.

Colonoscopy Cost Measure to be Tested for MIPS

Oct. 4, 2017

Prepare now to share your thoughts on the value of the measure with CMS.